News and Articles

Stories of Hope

Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.

Grant history

Hope, Funded

Every dollar below has been paid out to research, made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.

$7.1M

total research funding, fully paid out · as of November 2026

  1. 2024

    $3M awarded

    October
    $1M
    December
    $2M — announced Feb 2025

    To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.

  2. 2025

    $2.1M awarded

    September
    $1M
    December
    $1.1M — announced Jan 2026

    To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance, and to close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.

  3. 2026

    $2M awarded

    June
    $1M
    November
    $1M

    Through two grants to the Foundation Fighting Blindness, to fund gene-agnostic research: in June, the Gund Vision Fund (formerly the RD Fund) and early-stage gene therapy delivery research with Dr. Thomas Mendel; in November, the Gund Vision Fund and regenerative research with Dr. Jin Woo Kim at KAIST. The Gund Foundation Challenge matched the $1,475,000 directed to the Fund dollar for dollar.

Latest posts

Fundraiser stories

  1. Research

    Opus Genetics Treats First Participant in New Gene Therapy Trial for Retinal Disease

    Opus Genetics has officially treated the first participant in its Phase 1/2 clinical trial for OPGx-001 — a new gene therapy designed for individuals with LCA5-related Leber congenital amaurosis. This milestone marks the company’s first human trial and represents another important step forward in treating inherited retinal diseases. As more early-stage therapies enter clinical testing, hope continues to grow for families affected by progressive vision loss.

    Read more
  2. Gratitude gallery

    Gratitude in Motion: Real Reviews and Experiences From a Community Lifting Us Higher

    This Thanksgiving week, we’re honoring the power of community gratitude through real reviews and experiences shared by supporters who have encouraged, uplifted, and inspired our family. These heartfelt messages—from donors, parents, and individuals living with visual challenges—remind us that we’re not walking this journey alone. Their compassion fuels our mission to advance sight-saving science for children like Luke.

    Read more
  3. Research

    Long-Term Results Show Promise for MCO-010 in Retinitis Pigmentosa

    Long-Term Results Show Promise for RP Therapy At the 2025 ASRS meeting, researchers shared 2-year results showing that MCO-010, an optogenetic therapy, provided lasting vision improvements for patients with advanced retinitis pigmentosa. Unlike traditional gene therapies, MCO-010 is gene-agnostic, meaning it could help a broad range of patients regardless of mutation.

    Read more

All fundraiser stories